Mitochondrial dysfunction/NLRP3 inflammasome axis contributes to angiotensin II-induced skeletal muscle wasting via PPAR-γ

Abstract

Angiotensin II (Ang II) levels are elevated in patients with chronic kidney disease or heart failure, and directly causes skeletal muscle wasting in rodents, but the molecular mechanisms of Ang II-induced skeletal muscle wasting and its potential as a therapeutic target are unknown. We investigated the NLR family pyrin domain containing 3 (NLRP3) inflammasome-mediated muscle atrophy response to Ang II in C2C12 myotubes and Nlrp3 knockout mice. We also assessed the mitochondrial dysfunction (MtD)/NLRP3 inflammasome axis in Ang II-induced C2C12 myotubes. Finally, we examined whether a peroxisome proliferator-activated receptor-γ (PPAR-γ) agonist could attenuate skeletal muscle wasting by targeting the MtD/NLRP3 inflammasome axis in vitro and in vivo. We demonstrated that Ang II increased NLRP3 inflammasome activation in cultured C2C12 myotubes dose dependently. Nlrp3 knockdown or Nlrp3−/− mice were protected from the imbalance of protein synthesis and degradation. Exposure of C2C12 to Ang II increased mitochondrial ROS (mtROS) generation, accompanied by MtD. Remarkably, the mitochondrial-targeted antioxidant not only decreased mtROS and MtD, it also significantly inhibited NLRP3 inflammasome activation and restored skeletal muscle atrophy. Finally, the PPAR-γ agonist protected against Ang II-induced muscle wasting by preventing MtD, oxidative stress, and NLRP3 inflammasome activation in vitro and in vivo. This work suggests a potential role of MtD/NLRP3 inflammasome pathway in the pathogenesis of Ang II-induced skeletal muscle wasting, and targeting the PPAR-γ/MtD/NLRP3 inflammasome axis may provide a therapeutic approach for muscle wasting.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: NLRP3 inflammasome activation contributes to Ang II-induced muscle wasting in vitro.
Fig. 2: Nlrp3−/− mice ameliorated Ang II-induced muscle wasting in vivo.
Fig. 3: The mtROS/MtD/NLRP3 inflammasome axis is involved in Ang II-induced muscle wasting in C2C12 myotubes.
Fig. 4: The PPAR-γ agonist rosiglitazone attenuated Ang II-induced muscle wasting by inhibiting mtROS/MtD and NLRP3 inflammasome activation in C2C12 myotubes.
Fig. 5: The PPAR-γ antagonist T0070907 aggravated Ang II-induced muscle wasting by increasing mtROS/MtD and NLRP3 inflammasome activation in C2C12 myotubes.
Fig. 6: The PPAR-γ agonist rosiglitazone attenuated Ang II-induced muscle wasting in vivo.
Fig. 7: The PPAR-γ agonist rosiglitazone ameliorated muscle wasting by suppressing MtD and the NLRP3 inflammasome in vivo.
Fig. 8

References

  1. 1.

    Cohen S, Nathan JA, Goldberg AL. Muscle wasting in disease: molecular mechanisms and promising therapies. Nat Rev Drug Discov. 2015;14:58–74.

  2. 2.

    Yoshida T, Tabony AM, Galvez S, Galvez WE, Mitch Y, Higashi S, et al. Molecular mechanisms and signaling pathways of angiotensin II-induced muscle wasting: potential therapeutic targets for cardiac cachexia. Int J Biochem Cell Biol. 2013;45:2322–32.

  3. 3.

    Zhang L, Du J, Hu Z, Han G, Delafontaine P, Garcia G, et al. IL-6 and serum amyloid A synergy mediates angiotensin II-induced muscle wasting. J Am Soc Nephrol. 2009;20:604–12.

  4. 4.

    Brink M, Price SR, Chrast J, Bailey JL, Anwar A, Mitch WE, et al. Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor. Endocrinology. 2001;142:1489–96.

  5. 5.

    Mitsuishi M, Miyashita K, Muraki A, Itoh H. Angiotensin II reduces mitochondrial content in skeletal muscle and affects glycemic control. Diabetes. 2009;58:710–7.

  6. 6.

    Yoshida T, Galvez S, Tiwari S, Rezk BM, Semprun-Prieto L, Higashi Y, et al. Angiotensin II inhibits satellite cell proliferation and prevents skeletal muscle regeneration. J Biol Chem. 2013;288:23823–32.

  7. 7.

    Costamagna D, Costelli P, Sampaolesi M, Penna F. Role of inflammation in muscle homeostasis and myogenesis. Mediators Inflamm. 2015;2015:805172.

  8. 8.

    Jatoi A, Dakhil SR, Nguyen PL, Sloan JA, Kugler JW, Rowland KJ, et al. A placebo-controlled double blind trial of etanercept for the cancer anorexia/weight loss syndrome: results from N00C1 from the North Central Cancer Treatment Group. Cancer. 2007;110:1396–403.

  9. 9.

    Jatoi A, Ritter HL, Dueck A, Nguyen PL, Nikcevich DA, Luyun RF, et al. A placebo-controlled, double-blind trial of infliximab for cancer-associated weight loss in elderly and/or poor performance non-small cell lung cancer patients (N01C9). Lung Cancer. 2010;68:234–9.

  10. 10.

    Bayliss TJ, Smith JT, Schuster M, Dragnev KH, Rigas JR. A humanized anti-IL-6 antibody (ALD518) in non-small cell lung cancer. Expert Opin Biol Ther. 2011;11:1663–8.

  11. 11.

    Apel K, Hirt H. Reactive oxygen species: metabolism, oxidative stress, and signal transduction. Annu Rev Plant Biol. 2004;55:373–99.

  12. 12.

    Sukhanov S, Semprun-Prieto L, Yoshida T, Michael TA, Higashi Y, Galvez S, et al. Angiotensin II, oxidative stress and skeletal muscle wasting. Am J Med Sci. 2011;342:143–7.

  13. 13.

    Argiles JM, Lopez-Soriano FJ, Busquets S. Muscle wasting in cancer: the role of mitochondria. Curr Opin Clin Nutr Metab Care. 2015;18:221–5.

  14. 14.

    Tabony AM, Yoshida T, Sukhanov S, Delafontaine P. Protein phosphatase 2C-alpha knockdown reduces angiotensin II-mediated skeletal muscle wasting via restoration of mitochondrial recycling and function. Skelet Muscle. 2014;4:20.

  15. 15.

    Grygiel-Gorniak B. Peroxisome proliferator-activated receptors and their ligands: nutritional and clinical implications-a review. Nutr J. 2014;13:17.

  16. 16.

    Håkansson J, Eliasson B, Smith U, Enerback S. Adipocyte mitochondrial genes and the forkhead factor FOXC2 are decreased in type 2 diabetes patients and normalized in response to rosiglitazone. Diabetol Metab Syndr. 2011;3:32.

  17. 17.

    Corona JC, de Souza SC, Duchen MR. PPARgamma activation rescues mitochondrial function from inhibition of complex I and loss of PINK1. Exp Neurol. 2014;253:16–27.

  18. 18.

    Carta AR. PPAR-gamma: therapeutic prospects in Parkinson's disease. Curr Drug Targets. 2013;14:743–51.

  19. 19.

    Fogo AB. PPARgamma and chronic kidney disease. Pediatr Nephrol. 2011;26:347–51.

  20. 20.

    Bing C, Russell S, Becket E, Pope M, Tisdale MJ, Trayhurn P, et al. Adipose atrophy in cancer cachexia: morphologic and molecular analysis of adipose tissue in tumour-bearing mice. Br J Cancer. 2006;95:1028–37.

  21. 21.

    Beluzi M, Peres SB, Henriques FS, Sertie RA, Franco FO, Santos KB, et al. Pioglitazone treatment increases survival and prevents body weight loss in tumor-bearing animals: possible anti-cachectic effect. PLoS ONE. 2015;10:e122660.

  22. 22.

    Takeshita H, Yamamoto K, Nozato S, Inagaki T, Tsuchimochi H, Shirai M, et al. Modified forelimb grip strength test detects aging-associated physiological decline in skeletal muscle function in male mice. Sci Rep. 2017;7:42323.

  23. 23.

    Artlett CM, Thacker JD. Molecular activation of the NLRP3 Inflammasome in fibrosis: common threads linking divergent fibrogenic diseases. Antioxid Redox Signal. 2015;22:1162–75.

  24. 24.

    Bracey NA, Beck PL, Muruve DA, Hirota SA, Guo J, Jabagi H, et al. The Nlrp3 inflammasome promotes myocardial dysfunction in structural cardiomyopathy through interleukin-1beta. Exp Physiol. 2013;98:462–72.

  25. 25.

    Ding W, Guo H, Xu C, Wang B, Zhang M, Ding F. Mitochondrial reactive oxygen species-mediated NLRP3 inflammasome activation contributes to aldosterone-induced renal tubular cells injury. Oncotarget. 2016;7:17479–91.

  26. 26.

    Guo H, Bi X, Zhou P, Zhu S, Ding W. NLRP3 deficiency attenuates renal fibrosis and ameliorates mitochondrial dysfunction in a mouse unilateral ureteral obstruction model of chronic kidney disease. Mediators Inflamm. 2017;2017:8316560.

  27. 27.

    Boursereau R, Abou-Samra M, Lecompte S, Noel L, Brichard SM. Downregulation of the NLRP3 inflammasome by adiponectin rescues Duchenne muscular dystrophy. BMC Biol. 2018;16:33.

  28. 28.

    McBride MJ, Foley KP, D'Souza DM, Li YE, Lau TC, Hawke TJ, et al. The NLRP3 inflammasome contributes to sarcopenia and lower muscle glycolytic potential in old mice. Am J Physiol Endocrinol Metab. 2017;313:E222–E232.

  29. 29.

    Sun HJ, Ren XS, Xiong XQ, Chen YZ, Zhao MX, Wang JJ, et al. NLRP3 inflammasome activation contributes to VSMC phenotypic transformation and proliferation in hypertension. Cell Death Dis. 2017;8:e3074.

  30. 30.

    Dostert C, Pétrilli V, Van Bruggen R, Steele C, Mossman BT, Tschopp J. Innate immune activation through Nalp3 inflammasome sensing of asbestos and silica. Science. 2008;320:674–7.

  31. 31.

    Liu J, Peng Y, Feng Z, Shi W, Qu L, Li Y, et al. Reloading functionally ameliorates disuse-induced muscle atrophy by reversing mitochondrial dysfunction, and similar benefits are gained by administering a combination of mitochondrial nutrients. Free Radic Biol Med. 2014;69:116–28.

  32. 32.

    Cheng Y, Di S, Fan C, Cai L, Gao C, Jiang P, et al. SIRT1 activation by pterostilbene attenuates the skeletal muscle oxidative stress injury and mitochondrial dysfunction induced by ischemia reperfusion injury. Apoptosis. 2016;21:905–16.

  33. 33.

    Wei Y, Sowers JR, Nistala R, Gong H, Uptergrove GM, Clark SE, et al. Angiotensin II-induced NADPH oxidase activation impairs insulin signaling in skeletal muscle cells. J Biol Chem. 2006;281:35137–46.

  34. 34.

    Javeshghani D, Magder SA, Barreiro E, Quinn MT, Hussain SN. Molecular characterization of a superoxide-generating NAD(P)H oxidase in the ventilatory muscles. Am J Respir Crit Care Med. 2002;165:412–8.

  35. 35.

    Daiber A. Redox signaling (cross-talk) from and to mitochondria involves mitochondrial pores and reactive oxygen species. Biochim Biophys Acta. 2010;1797:897–906.

  36. 36.

    Ji Y, Liu J, Wang Z, Liu N, Gou W. PPARgamma agonist, rosiglitazone, regulates angiotensin II-induced vascular inflammation through the TLR4-dependent signaling pathway. Lab Invest. 2009;89:887–902.

Download references

Acknowledgements

This work was sponsored by Shanghai Pujiang Program (17PJD021), the interdisciplinary program of Shanghai Jiao Tong University (YG2017MS07), the distinguished Young Scholar of Ninth People’s Hospital (jyyq09201701), and the SHIPM-mu fund no. JC201805 from Shanghai Institute of Precision Medicine, Ninth People’s Hospital Shanghai affiliated to Jiao Tong University School of Medicine.

Author information

Correspondence to Wei Ding.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Liu, Y., Bi, X., Zhang, Y. et al. Mitochondrial dysfunction/NLRP3 inflammasome axis contributes to angiotensin II-induced skeletal muscle wasting via PPAR-γ. Lab Invest (2019). https://doi.org/10.1038/s41374-019-0355-1

Download citation